Dietary phytoestrogen intake is associated with reduced colorectal cancer risk

Journal of Nutrition

Volumn 136, Issue 12, 2006, Pages 3046-3053

  Cotterchio, Michelle ^a,b   Boucher, Beatrice A ^a   Manno, Michael ^a   Gallinger, Steven ^d   Okey, Allan ^c   Harper, Patricia ^e  

^a CANCER CARE ONTARIO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOL METHYLTRANSFERASE; ISOFLAVONE; LIGNAN; PHYTOESTROGEN;

ADULT; AGED; ARTICLE; CANADA; CANCER RESEARCH; CANCER RISK; COLORECTAL CANCER; CONTROLLED STUDY; DIETARY INTAKE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; QUESTIONNAIRE;

EID: 33845283897     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/136.12.3046     Document Type: Article

References (101)

1. National Cancer Institute of Canada (NCIC). Canadian cancer statistics 2004. Toronto: National Cancer Institute of Canada; 2004.
2. National Cancer Institute of Canada (NCIC). Canadian cancer statistics 2006. Toronto: National Cancer Institute of Canada; 2006.
3. Messina M, Barnes SJ. The role of soy products in reducing risk of cancer. J Natl Cancer Inst. 1991;83:541-6.
4. Murkies AL, Wilcox G, Davis SR. Phytoestrogens. J Clin Endocrinol Metab. 1998;83:297-303.
5. Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab. 1998;83:2223-35.
6. de Kleijn MJ, van der Schouw YT, Wilson PW, Adlercreutz H, Mazur W, Grobbee DE, Jacques PF. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham Study. J Nutr. 2001;131:1826-32.
7. Horn-Ross PL, Barnes S, Lee M, Coward L, Mandel JE, Koo J, John EM, Smith M. Assessing phytoestrogen exposure in epidemiologic studies: development of a database (United States). Cancer Causes Control. 2000;11:289-98.
8. Milder IEJ, Feskens EJM, Arts ICW, de Mesquita HBB, Hollman PCH, Kromhout D. Intake of the plant lignans secoisolariciresinol, matairesinol, lariciresinol, and pinoresinol in Dutch men and women. J Nutr. 2005;135:1202-7.
9. Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans and coumestan. Nutr Cancer. 2006;54:184-201.
10. Dai Q, Shu XO, Jin F, Potter JD, Kushi LH, Teas J, Gao YT, Zheng W. Population-based case-control study of soyfood intake and breast cancer risk in Shanghai. Br J Cancer. 2001;85:372-8.
11. McCann SE, Muti P, Vito D, Edge SB, Trevisan M, Freudenheim JL. Dietary lignan intakes and risk of pre-and post-menopausal breast cancer. Int J Cancer. 2004;111:440-3.
12. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, Howe GR, Dreon DM, et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:795-804.
13. Hughes I, Woods HF. Phytoestrogens and health. London: Food Standards Agency; 2003.
14. Anderson JJB, Anthony M, Messina M, Garner SC. Effects of phytooestrogens on tissues. Nutr Res Rev. 1999;12:75-116.
15. Messina M, Bennink M. Soyfoods, isoflavones and risk of colonic cancer: a review of the in vitro and in vivo data. Baillieres Clin Endocrinol Metab. 1998;12:707-28.
16. Thompson LU. Experimental studies on lignans and cancer. Baillieres Clin Endocrinol Metab. 1998;12:691-705.
17. Spector D, Anthony M, Alexander D, Arab L. Soy consumption and colorectal cancer. Nutr Cancer. 2003;47:1-12.
18. Le Marchand L, Hankin JH, Wilkens LR, Kolonel LN, Englyst HN, Lyu LC. Dietary fiber and colorectal cancer risk. Epidemiology. 1997;8:658-65.
19. Hoshiyama Y, Sekine T, Sasaba T. A case-control study of colorectal cancer and its relation to diet, cigarettes, and alcohol consumption in Saitama Prefecture, Japan. Tohoku J Exp Med. 1993;171:153-65.
20. Rossouw J, Anderson G, Prentice R, LaCroix A, Kooperberg C, Stefanick M, Jackson R, Beresford S, Howard B, et al. Writing group for the WHI investigators. JAMA. 2002;288:321-33.
21. Newcomb PA, Storer BE. Post-menopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst. 1995;87:1067-71.
22. Setchell KDR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr. 1998;68:S1333-46.
23. Krazeisen A, Breitling R, Möller G, Adamski J. Phytoestrogens inhibit human 17b-hydroxysteroid dehydrogenase type 5. Mol Cell Endocrinol. 2001;171:151-62.
24. Hu J, Liu Y, Yu YK, Zhao TZ, Liu SD, Wang QQ. Diet and cancer of the colon and rectum: a case-control study in China. Int J Epidemiol. 1991;20:362-7.
25. Inoue M, Tajima K, Hirose K, Hamajima N, Takezaki T, Hirai T, Kato T, Ohno Y. Subsite-specific risk factors for colorectal cancer: a hospital-based case-control study in Japan. Cancer Causes Control. 1995;6:14-22.
26. Nishi M, Yoshida K, Hirata K, Miyake H. Eating habits and colorectal cancer. Oncol Rep. 1997;4:995-8.
27. Seow A, Quah SR, Nyam D, Straughan PT, Chua T, Aw TC. Food groups and the risk of colorectal carcinoma in an Asian population. Cancer. 2002;95:2390-6.
28. Lechner D, Kallay E, Cross HS. Phytoestrogens and colorectal cancer prevention. Vitam Horm. 2005;70:169-98.
29. Carstensen B, Soll-Johanning H, Villadsen E, Sondergaard JO, Lynge E. Familial aggregation of colorectal cancer in the general population. Int J Cancer. 1996;68:428-35.
30. de Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M, Rossi G, Genuardi M, Neri G, et al. Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut. 1999;45:32-8.
31. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159-70.
32. Kulling SE, Honig DM, Simat TJ, Metzler M. Oxidative in vitro metabolism of the soy phytoestrogens daidzein and genistein. J Agric Food Chem. 2000;48:4963-72.
33. Roberts-Kirchhoff ES, Crowley JR, Hollenberg PF, Kim H. Metabolism of genistein by rat and human cytochrome P450s. Chem Res Toxicol. 1999;12:610-6.
34. Hu M, Krausz K, Chen J, Ge X, Li J, Gelboin HL, Gonzalez FJ. Identification of CYP1A2 as the main isoform for the phase I hydroxylated metabolism of genistein and a prodrug converting enzyme of methylated isoflavones. Drug Metab Dispos. 2003;31:924-31.
35. Dean B, Chang S, Doss GA, King C, Thomas PE. Glucuronidation, oxidative metabolism, and bioactivation of enterolactone in rhesus monkeys. Arch Biochem Biophys. 2004;429:244-51.
36. Tolleson WH, Doerge DR, Churchwell MI, Marques MM, Roberts DW. Metabolism of biochanin A and formononetin by human liver microsomes in vitro. J Agric Food Chem. 2002;50:4783-90.
37. Roberts DW, Doerge DR, Churchwell MI, Gamboa Da Costa G, Marques MM, Tolleson WH. Inhibition of extrahepatic human cytochromes P450 1A1 and 1B1 by metabolism of isoflavones found in Trifolium pratense (red clover). J Agric Food Chem. 2004;52:6623-32.
38. Kulling SE, Honig DM, Metzler M. Oxidative metabolism of the soy isoflavones daidzein and genistein in humans in vitro and in vivo. J Agric Food Chem. 2001;49:3024-33.
39. Cotterchio M, McKeown-Eyssen G, Sutherland H, Buchan G, Aronson M, Easson AM, Macey J, Holowaty E, Gallinger S. Ontario Familial Colon Cancer Registry: methods and first year response rates. Chron Dis Can. 2000;21:81-6.
40. Cotterchio M, Manno M, Klar N, McLaughlin J, Gallinger S. Colorectal screening is associated with reduced colorectal cancer risk: a case-study within the population-based Ontario Familial Colorectal Cancer Registry. Cancer Causes Control. 2005;16:865-75.
41. International Classification of Diseases. Manual of the International Statistical Classification of disease, injuries, and causes of death. Proceedings of the 9th Revision Conference. Geneva: World Health Organization; 1977.
42. Holowaty EJ, Lee G, Dale D, Chong N. A reabstraction study to estimate the accuracy and completeness of data elements in the Ontario Cancer Registry. Niagara-on-the-Lake (Ontario): American Association of Central Cancer Registries; 1994.
43. Vasen HFA, Mecklin JP, Khan PM, Lynch HT. The international collaborative group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991;34:424-5.
44. Stram DO, Hankin JH, Wilkens LR, Pike MC, Monroe KR, Park S, Henderson BE, Nomura AM, Earle ME, et al. Calibration of the dietary questionnaire for a multiethnic cohort in Hawaii and Los Angeles. Am J Epidemiol. 2000;151:358-70.
45. Mazur W, Fotsis T, Wahala K, Ojala S, Salakka A, Adlercreutz H. Isotope dilution gas chromatographic-mass spectrometric method for the determination of isoflavonoids, coumestrol, and lignans in food samples. Anal Biochem. 1996;233:169-80.
46. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H. Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr. 1998;79:37-45.
47. Mazur WM, Duke JA, Wahala K, Rasku S, Adlercreutz H. Isoflavonoids and lignans in legumes: nutritional and health aspects in humans. J Nutr Biochem. 1998;9:193-200.
48. Mazur W, Adlercreutz H. Natural and anthropogenic environmental oestrogens: the scientific basis for risk assessment. Naturally occurring oestrogens in food. Pure Appl Chem. 1998;70:1759-76.
49. Mazur WM, Uehara M, Wahala K, Adlercreutz H. Phyto-oestrogen content of berries, and plasma concentrations and urinary excretion of enterolactone after a single strawberry-meal in human subjects. Br J Nutr. 2000;83:381-7.
50. Pillow PC, Duphorne CM, Chang S, Contois JH, Strom SS, Spitz MR, Hursting SD. Development of a database for assessing dietary phytoestrogen intake. Nutr Cancer. 1999;33:3-19.
51. Valsta LM, Kilkkinen A, Mazur W, Nurmi T, Lampi AM, Ovaskainen ML, Korhonen T, Adlercreutz H, Pietinen P. Phyto-oestrogen database of foods and average intake in Finland. Br J Nutr. 2003;89 Suppl 1:S31-8.
52. Schlesselman JJ. Case-control studies. Design, conduct, analysis. Oxford: Oxford University Press; 1982.
53. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 2000.
54. Maldonado G, Greenland S. Simulation study by confounder-selection strategies. Am J Epidemiol. 1993;138:923-36.
55. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989;79:340-9.
56. Webb A, McCullough ML. Dietary lignans: potential role in cancer prevention. Nutr Cancer. 2005;51:117-31.
57. Horn-Ross PL, Lee M, John EM, Koo J. Sources of phytoestrogen exposure among non-Asian women in California, USA. Cancer Causes Control. 2000;11:299-302.
58. Hirayama T. Contribution of a long-term prospective cohort study to the issue of nutrition and cancer with special reference to the role of alcohol drinking. Prog Clin Biol Res. 1990;346:179-87.
59. Tajima K, Tominaga S. Dietary habits and gastrointestinal cancers: a comparative case-control study of stomach and large intestine cancers in Nagoya, Japan. Jpn J Cancer Res. 1985;76:705-16.
60. Davies MJ, Bowey EA, Adlercreutz H, Rowland IR, Rumsby PC. Effects of soy or rye supplementation of high-fat diets on colon tumour development in azoxymethane-treated rats. Carcinogenesis. 1999;20:927-31.
61. Serraino M, Thompson LU. Flaxseed supplementation and early markers of colon carcinogenesis. Cancer Lett. 1992;63:159-65.
62. Hakkak R, Korourian S, Ronis M, Johnston JM, Badger TM. Soy protein isolate consumption protects against azoxymethane-induced colon tumors in male rats. Cancer Lett. 2001;166:27-32.
63. Boucher B, Cotterchio M, Kreiger N, Nadalin V, Block T, Block G. Validity and reliability of the Block98 food-frequency questionnaire in a sample of Canadian women. Public Health Nutr. 2006;9:84-93.
64. Lampe JW. Isoflavonoid and lignan phytoestrogens as dietary biomarkers. J Nutr. 2003;133 Suppl 3:S956-64.
65. Ritchie MR, Morton MS, Deighton N, Blake A, Cummings JH. Plasma and urinary phyto-oestrogens as biomarkers of intake: validation by duplicate diet analysis. Br J Nutr. 2004;91:447-57.
66. Kilkkinen A, Valsta LM, Virtamo J, Stumpf K, Adlercreutz H, Pietinen P. Intake of lignans is associated with serum enterolactone concentration in Finnish men and women. J Nutr. 2003;133:1830-3.
67. Grace PB, Taylor JI, Low YL, Luben RN, Mulligan AA, Botting NP, Dowsett M,Welch AA, Khaw KT, et al. Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev. 2004;13:698-708.
68. Strauss L, Santti R, Saarinen N, Streng T, Joshi S, Makela S. Dietary phytoestrogens and their role in hormonally dependent disease. Toxicol Lett. 1998;102-103:349-54.
69. Haggans CJ, Hutchins AM, Olson BA, Thomas W, Martini MC, Slavin JL. Effect of flaxseed consumption on urinary estrogen metabolites in postmenopausal women. Nutr Cancer. 1999;33:188-95.
70. Lu LJW, Anderson KE, Grady JJ, Nagamani M. Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women. J Clin Endocrinol Metab. 2001;86:3045-52.
71. Lu LJ, Anderson KE, Grady JJ, Kohen F, Nagamani M. Decreased ovarian hormones during a soya diet: implications for breast cancer prevention. Cancer Res. 2000;60:4112-21.
72. Kampman E, Potter J, Slattery M, Caan B, Edwards S. Hormone replacement therapy, reproductive history, and colon cancer: a multicenter case-control study in the United States. Cancer Causes Control. 1997;8:146-58.
73. Fernandez E, La Vecchia C, Braga C, Talamini R, Negri E, Parazzini F, Franceschi S. Hormone replacement therapy and risk of colon and rectal cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:329-33.
74. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999;106:574-82.
75. McMichael A, Potter J. Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. J Natl Cancer Inst. 1980;65:1201-7.
76. Issa J, Ottaviano Y, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon cancer. Nat Genet. 1994;7:536-40.
77. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91:916-32.
78. Slattery M, Potter J, Curtin K, Edwards S, Ma KN, Anderson K, Schaffer D, Samowitz WS. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61:126-30.
79. English MA, Kane KF, Cruickshank N, Langman MJS, Stewart PM, Hewison M. Loss of estrogen inactivation in colonic cancer. J Clin Endocrinol Metab. 1999;84:2080-5.
80. Eliakim R, Abulafia O, Sherer D. Estrogen, progesterone and the gastrointestinal tract. J Reprod Med. 2000;45:781-8.
81. Rowland IR, Wiseman H, Sanders TAB, Adlercreutz H, Bowey EA. Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer. 2000;36:27-32.
82. Rowland I, Faughnan M, Hoey L,Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Brit J Nutr. 2003;89 Suppl 1:S45-58.
83. Niemeyer HB, Honig DM, Kulling SE, Metzler M. Studies on the metabolism of the plant lignans secoisolariciresinol and matairesinol. J Agric Food Chem. 2003;51:6317-25.
84. Bowey E, Adlercreutz H, Rowland I. Metabolism of isoflavones and lignans by the gut microflora: a study in germ-free and human flora associated rats. Food Chem Toxicol. 2003;41:631-6.
85. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood). 2005;230:155-70.
86. Kilkkinen A, Stumpf K, Pietinen P, Valsta LM, Tapanainen H, Adlercreutz H. Determinants of serum enterolactone concentration. Am J Clin Nutr. 2001;73:1094-100.
87. Martucci C, Fishman J. P450 enzymes of estrogen metabolism. Pharmacol Ther. 1993;57:237-57.
88. Yager JD, Liehr JG. Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol. 1996;36:203-32.
89. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, Inoue K. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999;20:1607-13.
90. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19:1-27.
91. Garte S. The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis. 1998;19:1329-32.
92. Smart J, Daly AK. Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics. 2000;10:11-24.
93. Cascorbi I, Brockmoller J, Roots IA. C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 1996;56:4965-9.
94. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo). 1999;125:803-8.
95. MacLeod SL, Tang YM, Yoko I. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc Am Assoc Cancer Res Meeting. 1998;39:396
96. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999;47:445-9.
97. Bailey LR, Roodi N, Dupont WD, Parl FF. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 1998;58:5038-41.
98. Stoilov I, Akarsu AN, Alozie I, Child A, Barsoum-Homsy M, Turacli ME, Or M, Lewis RA, Ozdemir N, et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet. 1998;62:573-84.
99. Dawling S, Roodi N, Mernaugh RL, Want X, Parl FF. Catechol-O- methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 2001;61:6716-22.
100. Slattery ML, Edwards SL, Samowitz W. Stage of colon cancer at diagnosis: implications for risk factor associations? Int J Epidemiol. 1998;27:382-7.
101. Colditz G, Atwood K, Emmons E, Monson RR, Willett WC, Trichopoulos D, Hunter DJ. Harvard Report on Cancer Prevention. Volume 4. Harvard Cancer Risk Index. Cancer Causes Control. 2000;11:477-88.